INT146549

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.54
First Reported 2007
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 10
Total Number 11
Disease Relevance 3.55
Pain Relevance 0.74

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (Ephx2) Golgi apparatus (Ephx2) nucleolus (Ephx2)
peroxisome (Ephx2) cytoplasm (Ephx2)
Anatomy Link Frequency
blood 2
eye 1
plasma 1
Ephx2 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Analgesic 1 99.80 Very High Very High Very High
Inflammation 6 99.24 Very High Very High Very High
IPN 2 98.48 Very High Very High Very High
Pain 6 98.28 Very High Very High Very High
Bioavailability 4 92.96 High High
Potency 1 80.56 Quite High
cINOD 3 46.16 Quite Low
Glutamate receptor 4 5.00 Very Low Very Low Very Low
medulla 4 5.00 Very Low Very Low Very Low
fibrosis 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Hypertension 49 100.00 Very High Very High Very High
Diabetes Mellitus 9 99.56 Very High Very High Very High
INFLAMMATION 6 99.24 Very High Very High Very High
Stroke 6 99.16 Very High Very High Very High
Dyslipidemia /

Combined Dyslipidemia

6 98.84 Very High Very High Very High
Inflammatory Pain 2 98.48 Very High Very High Very High
Pain 6 98.28 Very High Very High Very High
Cardiovascular Disease 2 97.60 Very High Very High Very High
Disease 6 97.44 Very High Very High Very High
Eye Disease 6 97.04 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In addition to selected in vitro and in vivo data of representative sEH inhibitors, a wide range of proposed applications of sEH inhibitors are also summarized.
Negative_regulation (inhibitors) of sEH
1) Confidence 0.54 Published 2010 Journal Expert Opin Ther Pat Section Body Doc Link 20429668 Disease Relevance 0.16 Pain Relevance 0
The clinical evaluation will be critical to assess the proclaimed therapeutic utility of sEH inhibition.


Negative_regulation (inhibition) of sEH
2) Confidence 0.40 Published 2010 Journal Expert Opin Ther Pat Section Body Doc Link 20429668 Disease Relevance 0.14 Pain Relevance 0
In addition to selected in vitro and in vivo data of representative sEH inhibitors, a wide range of proposed applications of sEH inhibitors are also summarized.
Negative_regulation (inhibitors) of sEH
3) Confidence 0.40 Published 2010 Journal Expert Opin Ther Pat Section Body Doc Link 20429668 Disease Relevance 0.16 Pain Relevance 0
AREAS COVERED IN THIS REVIEW: A comprehensive synopsis of patent literature on sEH inhibitors is provided.
Negative_regulation (inhibitors) of sEH
4) Confidence 0.40 Published 2010 Journal Expert Opin Ther Pat Section Body Doc Link 20429668 Disease Relevance 0.19 Pain Relevance 0
WHAT THE READER WILL GAIN: A total of more than 100 patent publications describing multiple classes of sEH inhibitors are analyzed.
Negative_regulation (inhibitors) of sEH
5) Confidence 0.40 Published 2010 Journal Expert Opin Ther Pat Section Body Doc Link 20429668 Disease Relevance 0.18 Pain Relevance 0
It has been claimed that sEH inhibitors can be used to treat hypertension, diabetes, stroke, dyslipidemia, pain, immunological disorders, eye diseases, neurological diseases and other indications.
Negative_regulation (inhibitors) of sEH in eye associated with pain, neurological disease, stroke, diabetes mellitus, hypertension and eye disease
6) Confidence 0.40 Published 2010 Journal Expert Opin Ther Pat Section Abstract Doc Link 20429668 Disease Relevance 0.69 Pain Relevance 0.10
Therefore, a group of highly potent compounds with more drug-like physiochemical properties were evaluated by monitoring their plasma profiles in dogs treated orally with sEH inhibitors.
Negative_regulation (inhibitors) of sEH in plasma
7) Confidence 0.38 Published 2010 Journal Eur J Pharm Sci Section Abstract Doc Link 20359531 Disease Relevance 0.32 Pain Relevance 0.20
N,N'-Disubstituted ureas are potent sEH inhibitors in vitro.
Negative_regulation (inhibitors) of sEH
8) Confidence 0.38 Published 2010 Journal Eur J Pharm Sci Section Abstract Doc Link 20359531 Disease Relevance 0.38 Pain Relevance 0.19
However, Ephx2 was not inhibited by ATCE, on the contrary.
Negative_regulation (inhibited) of Ephx2
9) Confidence 0.36 Published 2009 Journal Pflugers Arch Section Body Doc Link PMC2691531 Disease Relevance 0.35 Pain Relevance 0
Inhibition of Ephx2 has been shown to reduce blood pressure in various models of hypertension [20].
Negative_regulation (Inhibition) of Ephx2 in blood associated with hypertension
10) Confidence 0.36 Published 2009 Journal Pflugers Arch Section Body Doc Link PMC2691531 Disease Relevance 0.25 Pain Relevance 0
By inhibiting sEH, the increase in circulating EETs leads to a reduction in blood pressure in a number of animal models.
Negative_regulation (inhibiting) of sEH in blood
11) Confidence 0.25 Published 2007 Journal J. Cardiovasc. Pharmacol. Section Abstract Doc Link 17878749 Disease Relevance 0.64 Pain Relevance 0.25

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox